|
Motor Neuron Disease
|
0.310 |
Biomarker
|
disease |
BEFREE |
Using quantitative real-time PCR (Q-PCR), we show that Prx3 is also downregulated in spinal motor neurons from patients with both sporadic (sMND) and SOD1-related fMND.
|
16702190 |
2006 |
|
Motor Neuron Disease
|
0.310 |
Biomarker
|
disease |
CTD_human |
Using quantitative real-time PCR (Q-PCR), we show that Prx3 is also downregulated in spinal motor neurons from patients with both sporadic (sMND) and SOD1-related fMND.
|
16702190 |
2006 |
|
Osteoporosis, Age-Related
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Osteoporosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Osteoporosis, Senile
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Post-Traumatic Osteoporosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Anterior Horn Cell Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
|
16702190 |
2006 |
|
Lateral Sclerosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
|
16702190 |
2006 |
|
Familial Motor Neuron Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
|
16702190 |
2006 |
|
Motor Neuron Disease, Lower
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
|
16702190 |
2006 |
|
Motor Neuron Disease, Upper
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
|
16702190 |
2006 |
|
Motor Neuron Disease, Secondary
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen.
|
16702190 |
2006 |
|
Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.
|
16081686 |
2005 |
|
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.
|
16081686 |
2005 |
|
Insulin Resistance
|
0.200 |
Biomarker
|
phenotype |
RGD |
The two genes, pleckstrin homology domain-containing, family S member 1 (Plechs1) and peroxiredoxin III (Prdx3), were differentially expressed only in the obese rats, suggesting that these two genes are involved in the mild elevation of blood glucose levels and insulin resistance in obesity.
|
27523322 |
2016 |
|
Impaired glucose tolerance
|
0.200 |
Biomarker
|
phenotype |
RGD |
Plekhs1 and Prdx3 are candidate genes responsible for mild hyperglycemia associated with obesity in a new animal model of F344-fa-nidd6 rat.
|
27523322 |
2016 |
|
Liver carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
An upregulated expression of Prdx3 and Prdx5 has been reported in different cancer types, such as breast, ovarian, endometrial, and lung cancers, as well as in Hodgkin's lymphoma and hepatocellular carcinoma.
|
31500275 |
2019 |
|
Liver carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Importantly, matching these in vitro findings with HCC patient data revealed a panel of common molecular alterations including peroxiredoxin-3, epoxide hydrolase, transgelin-2 and collectin 12 that are clinically relevant for the patient's survival.
|
28994702 |
2017 |
|
Liver carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that PRDX3 promotes HCC growth and mediates cell migration and invasiveness and is a potential therapeutic target for HCC treatment.
|
26983019 |
2016 |
|
Liver carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The present study was conducted to investigate the response of PRX3 to oxidative stress in hepatocellular carcinoma (HCC) cells.
|
24105047 |
2014 |
|
Liver carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The results indicated that overexpression of PRDX3 was associated with 94.9% HCC, and correlated with poor differentiation (P<0.05), which suggest that PRDX3 has substantial clinical impact on the progression of hepatocarcinoma, and may be a potential therapeutic target for HCC.
|
22344546 |
2012 |
|
Liver carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
For the cell proliferation-related genes identified, expression levels of PRDX1 were relatively high in HCC samples from men, and expression levels of PRDX3 were relatively high in HCC samples from women.
|
15703822 |
2005 |
|
Liver carcinoma
|
0.070 |
AlteredExpression
|
disease |
LHGDN |
Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas.
|
12530083 |
2003 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The expression of Prdx3 and Prdx5 in different types of malignancies involves their association with different factors, such as transcription factors, micro RNAs, tumor suppressors, response elements, and oncogenic genes.
|
31500275 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Peroxiredoxin III Protects Tumor Suppressor PTEN from Oxidation by 15-Hydroperoxy-eicosatetraenoic Acid.
|
31636803 |
2019 |